WO2005110431A1 - Herbal product containing glucosamine - Google Patents

Herbal product containing glucosamine Download PDF

Info

Publication number
WO2005110431A1
WO2005110431A1 PCT/CA2005/000767 CA2005000767W WO2005110431A1 WO 2005110431 A1 WO2005110431 A1 WO 2005110431A1 CA 2005000767 W CA2005000767 W CA 2005000767W WO 2005110431 A1 WO2005110431 A1 WO 2005110431A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucosamine
rhizoma
radix
root
circulation
Prior art date
Application number
PCT/CA2005/000767
Other languages
French (fr)
Inventor
Frank Burczynski
Yuewen Gong
Xiaochen Gu
Gu Q. Wang
Original Assignee
University Of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Manitoba filed Critical University Of Manitoba
Publication of WO2005110431A1 publication Critical patent/WO2005110431A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/21Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236Ligusticum (licorice-root)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286Carthamus (distaff thistle)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/328Commiphora, e.g. mecca myrrh or balm of Gilead
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/50Fumariaceae (Fumitory family), e.g. bleeding heart
    • A61K36/505Corydalis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533Leonurus (motherwort)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537Salvia (sage)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736Prunus, e.g. plum, cherry, peach, apricot or almond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Pharmaceutical compositions comprising a low dosage of glucosamine and at least one circulation-enhancing herbal product, such as Suberect Spatholobus Stem (aulis Spatholobi), Motherwort herb (Herba Leonuri), Tumeric Root Tuber (Radix Curcumae), Medicinal Cyathula Root (Radix Cyathulae), Sanchi (Radix Notoginseng), Danshen Root (Radix Salviae Miltorrhizae), Szechwan Lovage Rhizome (Rhizoma Chuanxiong), Yanhusuo (Rhizoma Corydalis), Zedoray Rhizome (Rhizoma Curcumae), Common Burreed Tuber (Rhizoma Sparganni), Peach Seed (Semen Persicae), Safflower (Flos Carthami), Gummi Olibanum, or Myrrha, are described. The aforementioned glucosamine and circulation-enhancing herbal compositions can be used to treat joint pain, arthritis, amenorrhea, dysmenorrhea, and muscle weakness.

Description

HERBAL PRODUCT CONTAINING GLUCOSAMINE PRIOR APPLICATION INFORMATION This application claims the benefit of US Provisional Application 60/572,120, filed May 19, 2004.
FIELD OF THE INVENTION The present invention relates generally to the field of pharmaceutical compositions. More specifically, the present invention relates to a pharmaceutical composition comprising glucosamine and one or more natural herbs.
BACKGROUND OF THE INVENTION Glucosamine is an amino sugar and is a major constituent of hyaluronic acid. In the body, the compound is taken up by chondrocytes and used in the synthesis of hyaluronic acid. By increasing the amount of hyaluronic acid, glucosamine supplementation leads to the rehydration of cartilage. Glucosamine supplementation also leads to an increase in proteoglycans in the extracellular matrix of articular cartilage, thereby increasing the overall amount and the structural integrity of the cartilage. Glucosamine is also used by chondrocytes to produce glycosaminoglycans, which lead to the production of proteoglycans that hold and hydrate connective tissue. With glucosamine supplementation, chondrocytes may be able to replenish the cartilage matrix and synovial fluid when cartilage is damaged. US Published Patent Application 20020064568 teaches a compound for arresting the inflammatory response in affected tissues comprising a palatability agent, an herbal phytochemical and a metabolic precursor. The herbal phytochemical may be selected from the group consisting of cayenne, ginger, tumeric, yucca, Devil's Claw, nettle leaf, Black Cohosh, alfalfa and celery seeds. When the metabolic precursor is glucosamine, the composition comprises 50-2000 mg of glucosamine per 25 pounds of body weight Anecdotal evidence indicates that over time, the effectiveness of glucosamine at a specific dosage diminishes and the dosage must be increased. However, it has been shown that higher dosages of glucosamine lead to polyuria and polydipsia and it has also been theorized that high glucosamine levels may increase insulin resistance, thereby increasing the risk of diabetes (2003, JAVMA 222: 431-432). Polyuria and polydipsia can lead to altered disposition of concurrently administered medications (prescription or over the counter) and electrolyte imbalance. Depending on the medication this can be harmful to patients. Moreover, glucosamine has been reported to cause CNS effects such as drowsiness, headache, somnolence, dermatological and cardiovascular effects (increased blood pressure) (2005, J. Complementary Integrative Medicine (2(1) article 1). Glucosamine's mechanism of action for these side effects is not known. However, most side effects are dose dependent, i.e., increase dose increase the probability of adverse reactions. The ability to decrease the dose yet maintain the main physiologic effect would be highly desirable. Clearly, a pharmaceutical composition is needed which comprises a lower initial dosage of glucosamine but has similar effectiveness compared to higher dosages so that the benefits can be enjoyed for a longer period of time.
SUMMARY OF THE INVENTION According to a first aspect of the invention, there is provided a pharmaceutical composition comprising glucosamine and at least one circulation- enhancing herbal product.
DESCRIPTION OF THE PREFERRED EMBODIMENTS Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference. As used herein, "effective amount" refers to the administration of an amount of a given compound that achieves the desired effect, that is, the strengthening of cartilage and aiding in glycosaminoglycan synthesis. This provides its main benefit in osteoarthritis, enhanced mobility and decreased joint pain. Other physiological benefits of glucosamine include wound healing, psoriasis, inflammatory bowel disease and migraine prophylaxis. As used herein, the term "treating" in its various grammatical forms refers to preventing, curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of a disease state, disease progression, disease causitive agent other abnormal condition. Described herein is a pharmaceutical composition comprising glucosamine in combination with one or more herbal product that increases blood circulation. The herbal product may be selected from the group consisting of: Suberect Spatholobus Stem (aulis Spatholobi); Motherwort Herb (Herba Leonuri); Turmeric Root Tuber (Radix Curcumae); Medicinal Cyathula Root (Radix Cyathulae); Sanchi (Radix Notoginseng); Danshen Root (Radix Salviae Miltorrhizae); Szechwan Lovage Rhizome (Rhizoma Chuanxiong); Yanhusuo (Rhizoma Corydalis); Zedoray Rhizome (Rhizoma Curcumae); Common Burreed Tuber (Rhizoma Sparganii); Peach Seed (Semen Persicae), Safflower (Flos Carthami), Gummi Olibanum and Myrrha or combinations thereof. According to traditional Chinese herbal medicine these herbs are considered as "herbs that invigorate the blood" or "herbs that improve blood circulation and remove blood stasis" and therefore referred to herein as "circulation enhancing herbs" or "circulation enhancing herbal products". In the present case these herbs can be used alone or in combination with one or more other herbs, as discussed below. Some examples of these combinations include but are by no means limited to Peach Seed and Safflower, Suberect Spatholobus Stem and Turmeric Root Tuber, Zedoray Rhizome and Common Burreed Tuber, Gummi Olibanum and Myrrha, and Danshen Root and Szechwan Lovage Rhizome. As discussed below, the typical daily dosage of glucosamine on the market is approximately 43-257 mg per 25 lbs. However, as discussed herein, the addition of the herbal product improves blood circulation, meaning that a much lower amount of glucosamine can be used, for example, rather than the much higher dose of 43-257 mg/25 lbs, dosage can be reduced to 22-83 mg/ 25 lbs. As discussed above, the advantage of this arrangement is that the initial lower dosage is potentially less harmful and clearly less expensive. Furthermore, the dosage can be increased several times prior to reaching accepted threshold levels, as discussed above. Thus, in some embodiments, the pharmaceutical composition is in a tablet or capsule form which is arranged such that the dosage of glucosamine and circulation-improving herbal product in the tablet is approximately one-half of the dose that according to the instant invention is appropriate for an individual having an approximate weight of 175 pounds. That is, the dosage of a single tablet is such that an individual weighing 175 pounds would need to take 2 tablets. In these embodiments, the glucosamine may be at a dosage per tablet between 150-600 mg, as discussed above, and the herbal product or combination of herbal products may be at a dosage of 75-350 mg per tablet, as discussed below. As will be apparent to one of skill in the art, this is approximately 22-83 mg per 25 pounds per day. In one embodiment, the pharmaceutical composition comprises 300 mg glucosamine and 350 mg of an aqueous extract of Safflower (150 mg), common Flowering quince Fruit (150 mg), and Liquorice Root (50 mg). It is of note that in the traditional Chinese manner these three herbal products are combined. The Flowering quince fruit is useful for arthritis while the Liquorice Root is useful for those who are weak (lack of strength), or require pain relief (spasmodic pain in abdomen and limbs). In these embodiments, the dose would be 1-3 tablets daily (2 tablets for an average person of 175 lbs). Other examples of formulas include but are by no means limited to the following: Formula 1: glucosamine (100-400 mg), safflower (50-300 mg), peach seed
(20-50 mg), flowering quince fruit (50-300 mg), Liquorice Root (25-100 mg). Formula 2: glucosamine (100-400 mg), Suberect Spatholobus Stem (50-300 mg) and Turmeric Root Tuber (15-50 mg), flowering quince fruit (50-300 mg) and liquorice root (25-100 mg). Formula 3: glucosamine (100-400 mg), Zedoray Rhizome (30-50 mg), Common Burreed Tuber (20-50 mg), flowering quince fruit (50-300 mg), liquorice root (25-100 mg). Formula 4: glucosamine (100-400 mg), Gummi Olibanum (15-50 mg),
Myrrha (15-175 mg), flowering quince fruit (50-300 mg), liquorice root (25-100 mg). Formula 5: glucosamine (100-400 mg), Danshen Root (50-300 mg),
Szechwan Lovage Rhizome (10-30 mg), flowering quince fruit (50-300 mg), liquorice root (25-100 mg). Formula 6: glucosamine (100-400 mg), safflower (50-300 mg), flowering quince fruit (50-300 mg), liquorice root (25-100 mg), fructus mume (15-50 mg), herba ephedrae (15-50 mg). Formula 7: glucosamine (100-400 mg), safflower (50-300 mg), flowering quince fruit (50-300 mg), liquorice loot (25-100 mg), fructus mume (15-50 mg), ramulus cinnamomi cassiae (50-300 mg). In some embodiments, the aqueous extract is prepared by boiling the Safflower, common Flowering quince Fruit, and Liquorice Root in water for 1 hour. After the aqueous phase is decanted, more water is added and the material is boiled for an additional 30 minutes. The supernatant once again is decanted, additional water added and the material boiled for an additional 30 min. All aqueous phases are then combined and stored at 4°C overnight. The following day, the combined aqueous phases are centrifuged with the precipitate removed. Water is evaporated and the material concentrated and dried to powder form. Tablet filler and glucosamine are added and the tablet compressed or capsule formed. As will be appreciated by one of skill in the art, an effective amount of the above-described pharmaceutical composition may be used by an individual, for example, a mammal, to treat or ameliorate symptoms associated with one or more of the following: joint pain, arthritis, amenorrhea, dysmenorrhea and muscle weakness. The invention will now be described by way of examples. However, the invention is not limited to or limited by the examples.
EXAMPLE 1
Herbal Product Crude Product Extract Dosage (g) Dosage
(g) (mg)
Suberect Spatholobus Stem (aulis Spatholobi) 9-15 g 50-300
Motherwort Herb (Herba Leonuri) 9-30 g 50-600
Turmeric Root Tuber (Radix Curcumae) 3-9 g 15-50
Medicinal Cyathula Root (Radix Cyathulae) 4.5-9 g 20-50 Sanchi (Radix Notoginseng) 3-9 g 15-50
Danshen Root (Radix Salviae Miltorrhizae) 9-15 g 50-300
Szechwan Lovage Rhizome (Rhizoma Chuanxiong) 2-5 g 10-30
Yanhusuo (Rhizoma Corydalis) 3-9 g 15-50
Zedoray Rhizome (Rhizoma Curcumae) 6-9 g 30-50 Common Burreed Tuber (Rhizoma Sparganii) 4.5-9 g 20-50
Peach Seed (Semen Persicae) 4.5-9 g 20-50
Safflower (Flos Carthami) 9-15 g 50-300
Gummi Olibanum 3-9 g 15-50
Myrrha 3-12 g 15-175
As will be apparent to one of skill in the art, the doses indicated here represent the amount used in extraction of herbs. Other suitable amounts may be used and will of course depend on the nature and/or state of the herb used. An aqueous extract equivalent to the dosages shown in the Table above are extracted with a suitable solvent. The solvent is then evaporated and the remaining powder is reconstituted with tablet filler and glucosamine added, the powders are mixed appropriately and compressed to form the final tablet product. These concentrations can be used alone or in combination. Extraction methodology can use any volume that is reasonable for the manufacturing of the final product. Typically initial volumes used range 4-10 L.
EXAMPLE 2 We conducted an experiment whereby two groups of animals (rats) received either glucosamine alone or glucosamine and a herbal extract (the pharmaceutical composition comprises the equivalent of 300 mg glucosamine and 350 mg of an aqueous extract of Safflower (150 mg), common Flowering quince Fruit (150 mg), and Liquorice Root (50 mg)). Following 7 days of twice a day oral administration we took blood at 30, 45, and 60 minutes following oral administration on the last day of study. We analyzed the blood glucosamine concentration at these times and calculated the area under the concentration time curve (AUC). We found that glucosamine administered animals had 73.0 ug/ml/min while the glucosamine/herbal extract group had 114.9 ug/ml/min. Clearly the herbal group had almost twice as much glucosamine absorbed. While the preferred embodiments of the invention have been described above, it will be recognized and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.

Claims

CLAIMS 1. A pharmaceutical composition comprising glucosamine and at least one circulation-enhancing herbal product. 2. The pharmaceutical composition according to claim 1 wherein the circulation-enhancing herbal product is selected from the group consisting of:
Suberect Spatholobus Stem (aulis Spatholobi); Motherwort Herb (Herba Leonuri); Turmeric Root Tuber (Radix Curcumae); Medicinal Cyathula Root (Radix Cyathulae); Sanchi (Radix Notoginseng); Danshen Root (Radix Salviae Miltorrhizae); Szechwan Lovage Rhizome (Rhizoma Chuanxiong); Yanhusuo (Rhizoma Corydalis); Zedoray Rhizome (Rhizoma Curcumae); Common Burreed Tuber (Rhizoma Sparganii); Peach Seed (Semen Persicae) Safflower (Flos Carthami), Gummi Olibanum and Myrrha. 3. The pharmaceutical composition according to claim 1 wherein the glucosamine is at a dosage of 100-500 mg. 4. The pharmaceutical composition according to claim 1 wherein the circulation-enhancing herbal product is at a dosage of 15-600 mg.
PCT/CA2005/000767 2004-05-19 2005-05-19 Herbal product containing glucosamine WO2005110431A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57212004P 2004-05-19 2004-05-19
US60/572,120 2004-05-19

Publications (1)

Publication Number Publication Date
WO2005110431A1 true WO2005110431A1 (en) 2005-11-24

Family

ID=35393988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2005/000767 WO2005110431A1 (en) 2004-05-19 2005-05-19 Herbal product containing glucosamine

Country Status (1)

Country Link
WO (1) WO2005110431A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102488763A (en) * 2011-12-28 2012-06-13 吕慧侠 Composition with functions of treating dysmenorrhoea and beautifying
CN102526389A (en) * 2012-03-09 2012-07-04 王利伟 Traditional Chinese medicine for treating myasthenia gravis and amyotrophy
CN102526359A (en) * 2012-02-15 2012-07-04 张秀兰 Medicine for treating plantar fasciitis and preparation method for medicine
CN102552422A (en) * 2012-02-13 2012-07-11 金纯� Hemorrhoids acupoint plaster
CN102579634A (en) * 2012-02-23 2012-07-18 熊桂华 Externally applied traditional Chinese medicine composition for treating knee osteoarthritis (OA)
CN102614343A (en) * 2012-05-01 2012-08-01 马守云 Medicament for treating dysmenorrhea
CN102631453A (en) * 2012-05-09 2012-08-15 张静 External medicament for treating hyperplasia of mammary glands and ovarian cyst
CN102641338A (en) * 2012-05-15 2012-08-22 山东省血液中心 Massage medicament for treating soft tissue injury
CN102670732A (en) * 2012-05-29 2012-09-19 陕西新药技术开发中心 Medicament for treating headache
CN102697880A (en) * 2012-06-27 2012-10-03 陈慧婷 Chinese angelica Chinese medicinal preparation for treating dizziness and preparation method thereof
CN103083473A (en) * 2011-11-08 2013-05-08 谢朝云 Medicament for treating heart disease and preparation method thereof
CN103083489A (en) * 2013-01-24 2013-05-08 王林祥 Traditional Chinese medicine wine for treating lumbar spondylosis, cervical spondylosis, early osteoproliferation and old wounds
CN103142722A (en) * 2013-03-13 2013-06-12 辛秀芳 Traditional Chinese medicine composition for treating liver qi depression type irregular menstruation
CN103239520A (en) * 2013-04-17 2013-08-14 宁夏张氏回医正骨医院 Moslemic ointment for treating osteoarthritis and preparation method of moslemic ointment
CN103393797A (en) * 2013-08-09 2013-11-20 黄文珍 Traditional Chinese medicine composition for treating dysmenorrhea of women and preparation method thereof
CN104013780A (en) * 2014-06-27 2014-09-03 三明三药兽药有限公司 Traditional Chinese medicine composition, traditional Chinese medicine preparation process and application of traditional Chinese medicine in field of veterinary medicament
CN104173667A (en) * 2014-08-25 2014-12-03 吕红权 Traditional Chinese medicine composition for treating osteoarthritis
CN104352966A (en) * 2014-10-28 2015-02-18 王丽娟 Traditional Chinese medicine composition for treating dysmenorrhea
CN104434951A (en) * 2014-11-19 2015-03-25 威海斯瑞海洋生物科技有限公司 New application of chitosan and derivatives thereof
CN104688941A (en) * 2015-03-17 2015-06-10 苏州市天灵中药饮片有限公司 Traditional Chinese medicine decoction for relieving dysmenorrhea and preparation method thereof
CN104825725A (en) * 2015-06-08 2015-08-12 刘云平 Traditional Chinese medicine for treating dysmenorrhea
CN104893914A (en) * 2015-05-13 2015-09-09 河南省新境界酒业有限公司 Health wine with tendons relaxing and collaterals activating functions
CN105012878A (en) * 2015-07-30 2015-11-04 王华荣 Traditional Chinese medicine composition for treating dysmenorrhea
CN114470141A (en) * 2022-04-19 2022-05-13 深圳德荫堂生物科技有限公司 Biological agent for anti-inflammation protection of bone joint and production method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916565A (en) * 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
US6333304B1 (en) * 1999-04-20 2001-12-25 Teresa K. Bath Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue
US20020037314A1 (en) * 1999-03-19 2002-03-28 Meisner Lorraine Faxon Compositions and methods
US6492429B1 (en) * 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
US6579543B1 (en) * 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
US20040121024A1 (en) * 2002-12-19 2004-06-24 Gorsek Wayne F. Composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and improved joint function

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916565A (en) * 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
US20020037314A1 (en) * 1999-03-19 2002-03-28 Meisner Lorraine Faxon Compositions and methods
US6333304B1 (en) * 1999-04-20 2001-12-25 Teresa K. Bath Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue
US6492429B1 (en) * 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
US6579543B1 (en) * 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
US20040121024A1 (en) * 2002-12-19 2004-06-24 Gorsek Wayne F. Composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and improved joint function

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103083473A (en) * 2011-11-08 2013-05-08 谢朝云 Medicament for treating heart disease and preparation method thereof
CN102488763A (en) * 2011-12-28 2012-06-13 吕慧侠 Composition with functions of treating dysmenorrhoea and beautifying
CN102488763B (en) * 2011-12-28 2014-01-08 江苏普诺生生物科技有限公司 Composition with functions of treating dysmenorrhoea and beautifying
CN102552422A (en) * 2012-02-13 2012-07-11 金纯� Hemorrhoids acupoint plaster
CN102526359A (en) * 2012-02-15 2012-07-04 张秀兰 Medicine for treating plantar fasciitis and preparation method for medicine
CN102526359B (en) * 2012-02-15 2013-08-28 张秀兰 Medicine for treating plantar fasciitis and preparation method for medicine
CN102579634A (en) * 2012-02-23 2012-07-18 熊桂华 Externally applied traditional Chinese medicine composition for treating knee osteoarthritis (OA)
CN102526389A (en) * 2012-03-09 2012-07-04 王利伟 Traditional Chinese medicine for treating myasthenia gravis and amyotrophy
CN102614343A (en) * 2012-05-01 2012-08-01 马守云 Medicament for treating dysmenorrhea
CN102631453A (en) * 2012-05-09 2012-08-15 张静 External medicament for treating hyperplasia of mammary glands and ovarian cyst
CN102641338A (en) * 2012-05-15 2012-08-22 山东省血液中心 Massage medicament for treating soft tissue injury
CN102670732A (en) * 2012-05-29 2012-09-19 陕西新药技术开发中心 Medicament for treating headache
CN102670732B (en) * 2012-05-29 2014-12-03 陕西新药技术开发中心 Medicament for treating headache
CN102697880A (en) * 2012-06-27 2012-10-03 陈慧婷 Chinese angelica Chinese medicinal preparation for treating dizziness and preparation method thereof
CN103083489A (en) * 2013-01-24 2013-05-08 王林祥 Traditional Chinese medicine wine for treating lumbar spondylosis, cervical spondylosis, early osteoproliferation and old wounds
CN103142722A (en) * 2013-03-13 2013-06-12 辛秀芳 Traditional Chinese medicine composition for treating liver qi depression type irregular menstruation
CN103239520A (en) * 2013-04-17 2013-08-14 宁夏张氏回医正骨医院 Moslemic ointment for treating osteoarthritis and preparation method of moslemic ointment
CN103393797A (en) * 2013-08-09 2013-11-20 黄文珍 Traditional Chinese medicine composition for treating dysmenorrhea of women and preparation method thereof
CN104013780B (en) * 2014-06-27 2017-08-01 三明三药兽药有限公司 The application of Chinese medicine composition, preparation technique of traditional Chinese medicine and the Chinese medicine in field of veterinary
CN104013780A (en) * 2014-06-27 2014-09-03 三明三药兽药有限公司 Traditional Chinese medicine composition, traditional Chinese medicine preparation process and application of traditional Chinese medicine in field of veterinary medicament
CN104173667A (en) * 2014-08-25 2014-12-03 吕红权 Traditional Chinese medicine composition for treating osteoarthritis
CN104173667B (en) * 2014-08-25 2017-10-20 王政乾 A kind of Chinese medicine composition for treating Osteoarthritis
CN104352966A (en) * 2014-10-28 2015-02-18 王丽娟 Traditional Chinese medicine composition for treating dysmenorrhea
CN104434951A (en) * 2014-11-19 2015-03-25 威海斯瑞海洋生物科技有限公司 New application of chitosan and derivatives thereof
CN104688941A (en) * 2015-03-17 2015-06-10 苏州市天灵中药饮片有限公司 Traditional Chinese medicine decoction for relieving dysmenorrhea and preparation method thereof
CN104893914A (en) * 2015-05-13 2015-09-09 河南省新境界酒业有限公司 Health wine with tendons relaxing and collaterals activating functions
CN104825725A (en) * 2015-06-08 2015-08-12 刘云平 Traditional Chinese medicine for treating dysmenorrhea
CN105012878A (en) * 2015-07-30 2015-11-04 王华荣 Traditional Chinese medicine composition for treating dysmenorrhea
CN114470141A (en) * 2022-04-19 2022-05-13 深圳德荫堂生物科技有限公司 Biological agent for anti-inflammation protection of bone joint and production method thereof

Similar Documents

Publication Publication Date Title
WO2005110431A1 (en) Herbal product containing glucosamine
CN101933991B (en) Analgesic and anti-inflammatory medicament and preparation method thereof
CN103386022B (en) Chinese medicine composition for treating tuberculous pleurisy
CN101926882A (en) Medicinal composition for treating cancer and preparation methods thereof
CN103705578B (en) There is blood fat reducing and Chinese medicine preparation suppressing blood glucose rising effect and preparation method thereof
CN101433597A (en) Chinese medicinal composition with function for reducing blood sugar and preparation method thereof
CN107260825A (en) A kind of pharmaceutical composition for treating sty
CN101361880B (en) Compound Gansu julid medicine for gastrosis
Li et al. Progress on traditional Chinese medicine in improving hepatic fibrosis through inhibiting oxidative stress
CN1202852C (en) Traditional Chinese medicine for treating wind-cold type of common cold and preparation process thereof
CN1410093A (en) Medicine for treating cyst
CN100571739C (en) Herbal mixture of treatment cardiovascular disease and preparation method thereof
CN1269518C (en) Compound medicine for treating tuberculosis and its preparing method
CN102824446B (en) Medicinal composition with anti-fatigue effect as well as preparation method and application thereof
CN102742832A (en) Dietetic therapy product for protecting joint and preparation method thereof
CN1813876A (en) Xian Pengliaofu oral preparation-a Chinese medicine for treating bone disease
CN1843493A (en) Externally applied medicine for relieving pain and preparation method thereof
CN104383283A (en) Oral medicine for treating enteritis and dysentery
CN105770478A (en) Traditional Chinese medicine composition for treating bladder cancer
CN109432115A (en) A kind of drug and application thereof for treating primary dysmenorrhea
CN104208485A (en) Pharmaceutical preparation for reducing blood sugar as well as preparation method and application of pharmaceutical preparation
CN101104004A (en) Medicine for treating hyperosteogeny and rheumatic arthritis and its preparing method
CN103263516B (en) Medicine for treating cholecystitis
CN101961395A (en) Chinese traditional medicine for treating tumors by matching with berchemia lineata
CN102198244B (en) Medicament for treating gastric and duodenal ulcers, gastritis and other diseases and preparation method thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase